{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T07:09:58Z","timestamp":1793084998864,"version":"4.5.0"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,2,19]],"date-time":"2020-02-19T00:00:00Z","timestamp":1582070400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,2,19]],"date-time":"2020-02-19T00:00:00Z","timestamp":1582070400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005969","name":"Universit\u00e0 di Bologna","doi-asserted-by":"publisher","award":["RFO Unibo"],"award-info":[{"award-number":["RFO Unibo"]}],"id":[{"id":"10.13039\/501100005969","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Vet Res"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Background<\/jats:title>\n<jats:p>Gain-of-function mutations in KIT are driver events of oncogenesis in mast cell tumours (MCTs) affecting companion animals. Somatic mutations of KIT determine the constitutive activation of the tyrosine kinase receptor leading to a worse prognosis and a shorter survival time than MCTs harbouring wild-type KIT. However, canine MCTs carrying KIT somatic mutations generally respond well to tyrosine kinase inhibitors; hence their presence represents a predictor of treatment effectiveness, and its detection allows implementing a stratified medical approach. Despite this, veterinary oncologists experience treatment failures, even with targeted therapies whose cause cannot be elucidated. The first case of an MCT-affected dog caused by a secondary mutation in the tyrosine kinase domain responsible for resistance has recently been reported. The knowledge of this and all the other mutations responsible for resistance would allow the effective bedside implementation of a deeply stratified and more effective medical approach.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Case presentation<\/jats:title>\n<jats:p>The second case of a canine MCT carrying a different resistance mutation is herein described. The case was characterised by aggressive behaviour and early metastasis unresponsive to both vinblastine- and masitinib-based treatments. Molecular profiling of the tumoural masses revealed two different mutations; other than the already known activating mutation p.Asn508Ile in <jats:italic>KIT<\/jats:italic> exon 9, which is tyrosine kinase inhibitor-sensitive, a nearly adjacent secondary missense mutation, p.Ala510Val, which had never before been described, was detected. In vitro transfection experiments showed that the secondary mutation did not cause the constitutive activation by itself but played a role in conferring resistance to masitinib.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Conclusions<\/jats:title>\n<jats:p>This study highlighted the importance of the accurate molecular profiling of an MCT in order to improve understanding of the molecular mechanism underlying tumourigenesis and reveal chemoresistance in MCTs for more effective therapies. The detection of the somatic mutations responsible for resistance should be included in the molecular screening of MCTs, and a systematic analysis of all the cases characterised by unexpected refractoriness to therapies should be investigated in depth at both the genetic and the phenotypic level.<\/jats:p>\n<\/jats:sec>","DOI":"10.1186\/s12917-020-02284-9","type":"journal-article","created":{"date-parts":[[2020,2,19]],"date-time":"2020-02-19T12:03:52Z","timestamp":1582113832000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["The secondary KIT mutation p.Ala510Val in a cutaneous mast cell tumour carrying the activating mutation p.Asn508Ile confers resistance to masitinib in dogs"],"prefix":"10.1186","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0970-4827","authenticated-orcid":false,"given":"Fabio","family":"Gentilini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Elena","family":"Turba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Dally","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masamine","family":"Takanosu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sena","family":"Kurita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Bonkobara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,2,19]]},"reference":[{"key":"2284_CR1","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/S0301-472X(98)00075-7","volume":"27","author":"CA London","year":"1999","unstructured":"London CA, Galli SJ, Yuuki T, Hu ZQ, Helfand SC, Geissler EN. Spontaneous canine mast cell tumors express tandem duplications in the proto-oncogene c-kit. Exp Hematol. 1999;27:689\u201397.","journal-title":"Exp Hematol"},{"key":"2284_CR2","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1046\/j.1523-1747.1999.00488.x","volume":"112","author":"Y Ma","year":"1999","unstructured":"Ma Y, Longley BJ, Wang X, Blount JL, Langley K, Caughey GH. Clustering of activating mutations in c-KIT\u2019s juxtamembrane coding region in canine mast cell neoplasms. J Invest Dermatol. 1999;112:165\u201370.","journal-title":"J Invest Dermatol"},{"issue":"1","key":"2284_CR3","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1354\/vp.40-1-42","volume":"40","author":"D Frost","year":"2003","unstructured":"Frost D, Lasota J, Miettinen M. Gastrointestinal stromal tumors and leiomyomas in the dog: a histopathologic immunohistochemical and molecular genetic study of 50 cases. Vet Pathol. 2003;40(1):42\u201354.","journal-title":"Vet Pathol"},{"key":"2284_CR4","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1593\/neo.05622","volume":"8","author":"JD Webster","year":"2006","unstructured":"Webster JD, Yuzbasiyan-Gurkan V, Kaneene JB, Miller R, Resau JH, Kiupel M. The role of c-KIT in tumorigenesis: evaluation in canine cutaneous mast cell tumors. Neoplasia. 2006;8:104\u201311.","journal-title":"Neoplasia"},{"key":"2284_CR5","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1158\/1541-7786.MCR-08-0067","volume":"6","author":"S Letard","year":"2008","unstructured":"Letard S, Yang Y, Hanssens K, Moussy A, Kinet JP, Hermine O, et al. Gain-of-function mutations in the extracellular domain of KIT are common in canine mast cell tumors. Mol Cancer Res. 2008;6:1137\u201345.","journal-title":"Mol Cancer Res"},{"key":"2284_CR6","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1177\/0300985813478211","volume":"50","author":"S Hayes","year":"2013","unstructured":"Hayes S, Yuzbasiyan-Gurkan V, Gregory-Bryson E, Kiupel M. Classification of canine nonangiogenic nonlymphogenic gastrointestinal sarcomas based on microscopic immunohistochemical and molecular characteristics. Vet Pathol. 2013;50:779\u201388.","journal-title":"Vet Pathol"},{"key":"2284_CR7","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.tvjl.2014.12.015","volume":"205","author":"M Bonkobara","year":"2015","unstructured":"Bonkobara M. Dysregulation of tyrosine kinases and use of imatinib in small animal practice. Vet J. 2015;205:180\u20138.","journal-title":"Vet J"},{"key":"2284_CR8","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.tvjl.2015.10.051","volume":"207","author":"M Takanosu","year":"2016","unstructured":"Takanosu M, Amano S, Kagawa Y. Analysis of c-KIT exon 11 mutations in canine gastrointestinal stromal tumours. Vet J. 2016;207:118\u201323.","journal-title":"Vet J"},{"key":"2284_CR9","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/1746-6148-4-32","volume":"4","author":"JD Webster","year":"2008","unstructured":"Webster JD, Yuzbasiyan-Gurkan V, Thamm DH, Hamilton E, Kiupel M. Evaluation of prognostic markers for canine mast cell tumors treated with vinblastine and prednisone. BMC Vet Res. 2008;4:32.","journal-title":"BMC Vet Res"},{"key":"2284_CR10","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.vetimm.2010.05.009","volume":"137","author":"Y Takeuchi","year":"2010","unstructured":"Takeuchi Y, Fujino Y, Watanabe M, Nakagawa T, Ohno K, Sasaki N, et al. Aberrant autophosphorylation of c-kit receptor in canine mast cell tumor cell lines. Vet Immunol Immunopathol. 2010;137:208\u201316.","journal-title":"Vet Immunol Immunopathol"},{"key":"2284_CR11","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1177\/0300985810386469","volume":"48","author":"M Kiupel","year":"2011","unstructured":"Kiupel M, Webster JD, Bailey KL, Best S, DeLay J, Detrisac CJ, et al. Proposal of a 2-tier histologic grading system for canine cutaneous mast cell tumors to more accurately predict biological behavior. Vet Pathol. 2011;48:147\u201355.","journal-title":"Vet Pathol"},{"key":"2284_CR12","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.tvjl.2012.11.018","volume":"196","author":"Y Takeuchi","year":"2013","unstructured":"Takeuchi Y, Fujino Y, Watanabe M, Takahashi M, Nakagawa T, Takeuchi A, et al. Validation of the prognostic value of histopathological grading or c-kit mutation in canine cutaneous mast cell tumours: a retrospective cohort study. Vet J. 2013;196:492\u20138.","journal-title":"Vet J"},{"key":"2284_CR13","doi-asserted-by":"crossref","first-page":"765","DOI":"10.2460\/javma.246.7.765","volume":"246","author":"D Stefanello","year":"2015","unstructured":"Stefanello D, Buracco P, Sabattini S, Finotello R, Giudice C, Grieco V, et al. Comparison of 2- and 3-category histologic grading systems for predicting the presence of metastasis at the time of initial evaluation in dogs with cutaneous mast cell tumors: 386 cases (2009-2014). J Am Vet Med Assoc. 2015;246:765\u20139.","journal-title":"J Am Vet Med Assoc"},{"key":"2284_CR14","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1111\/vco.12140","volume":"15","author":"J Smith","year":"2017","unstructured":"Smith J, Kiupel M, Farrelly J, Cohen R, Olmsted G, Kirpensteijn J, et al. Recurrence rates and clinical outcome for dogs with grade II mast cell tumours with a low AgNOR count and Ki67 index treated with surgery alone. Vet Comp Oncol. 2017;15:36\u201345.","journal-title":"Vet Comp Oncol"},{"key":"2284_CR15","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1182\/blood.V99.5.1741","volume":"99","author":"Y Ma","year":"2002","unstructured":"Ma Y, Zeng S, Metcalfe DD, Akin C, Dimitrijevic S, Butterfield JH, et al. The c-KIT mutation causing human mastocytosis is resistant to STI571 and other KIT kinase inhibitors; kinases with enzymatic site mutations show different inhibitor sensitivity profiles than wild-type kinases and those with regulatory-type mutations. Blood. 2002;99:1741\u20134.","journal-title":"Blood"},{"key":"2284_CR16","doi-asserted-by":"crossref","first-page":"5913","DOI":"10.1158\/0008-5472.CAN-04-0085","volume":"64","author":"LL Chen","year":"2004","unstructured":"Chen LL, Trent JC, Wu EF, Fuller GN, Ramdas L, Zhang W, et al. A missense mutation in KIT kinase domain 1 correlates with imatinib resistance in gastrointestinal stromal tumors. Cancer Res. 2004;64:5913\u20139.","journal-title":"Cancer Res"},{"key":"2284_CR17","doi-asserted-by":"crossref","first-page":"4182","DOI":"10.1158\/1078-0432.CCR-04-2245","volume":"11","author":"CR Antonescu","year":"2005","unstructured":"Antonescu CR, Besmer P, Guo T, Arkun K, Hom G, Koryotowski B, et al. Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation. Clin Cancer Res. 2005;11:4182\u201390.","journal-title":"Clin Cancer Res"},{"key":"2284_CR18","doi-asserted-by":"crossref","first-page":"7593","DOI":"10.1158\/1078-0432.CCR-05-0710","volume":"11","author":"N Theou","year":"2005","unstructured":"Theou N, Gil S, Devocelle A, Julie C, Lavergne-Slove A, Beauchet A, et al. Multidrug resistance proteins in gastrointestinal stromal tumors: site-dependent expression and initial response to imatinib. Clin Cancer Res. 2005;11:7593\u20138.","journal-title":"Clin Cancer Res"},{"key":"2284_CR19","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1016\/S1470-2045(07)70342-X","volume":"8","author":"JF Apperley","year":"2007","unstructured":"Apperley JF. Part I: mechanisms of resistance to imatinib in chronic myeloid leukaemia. Lancet Oncol. 2007;8:1018\u201329.","journal-title":"Lancet Oncol"},{"key":"2284_CR20","doi-asserted-by":"crossref","first-page":"3909","DOI":"10.1038\/sj.onc.1210173","volume":"26","author":"D Mahadevan","year":"2007","unstructured":"Mahadevan D, Cooke L, Riley C, Swart R, Simons B, Della Croce K, et al. A novel tyrosine kinase switch is a mechanism of imatinib resistance in gastrointestinal stromal tumors. Oncogene. 2007;26:3909\u201319.","journal-title":"Oncogene"},{"key":"2284_CR21","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1111\/j.1349-7006.2008.00727.x","volume":"99","author":"T Nishida","year":"2008","unstructured":"Nishida T, Kanda T, Nishitani A, Takahashi T, Nakajima K, Ishikawa T, et al. Secondary mutations in the kinase domain of the KIT gene are predominant in imatinib-resistant gastrointestinal stromal tumor. Cancer Sci. 2008;99:799\u2013804.","journal-title":"Cancer Sci"},{"key":"2284_CR22","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1111\/ejh.12526","volume":"95","author":"M Kobayashi","year":"2015","unstructured":"Kobayashi M, Kuroki S, Tanaka Y, Moriya Y, Kozutumi Y, Uehara Y, et al. Molecular changes associated with the development of resistance to imatinib in an imatinib-sensitive canine neoplastic mast cell line carrying a KIT c1523A>T mutation. Eur J Haematol. 2015;95:524\u201331.","journal-title":"Eur J Haematol"},{"key":"2284_CR23","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.vetimm.2017.05.004","volume":"188","author":"Y Nakano","year":"2017","unstructured":"Nakano Y, Kobayashi M, Bonkobara M, Takanosu M. Identification of a secondary mutation in the KIT kinase domain correlated with imatinib-resistance in a canine mast cell tumor. Vet Immunol Immunopathol. 2017;188:84\u20138.","journal-title":"Vet Immunol Immunopathol"},{"key":"2284_CR24","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1111\/jvp.12816","volume":"42","author":"S Kurita","year":"2019","unstructured":"Kurita S, Miyamoto R, Tani H, Kobayashi M, Sasaki T, Tamura K, et al. Genetic alterations of KIT during clonal expansion and subsequent acquisition of resistance to toceranib in a canine mast cell tumor cell line. J Vet Pharmacol Ther. 2019;42:673\u201381.","journal-title":"J Vet Pharmacol Ther"},{"key":"2284_CR25","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1111\/vco.12039","volume":"13","author":"F Gentilini","year":"2015","unstructured":"Gentilini F, Mantovani V, Turba ME. The use of COLD-PCR DHPLC and GeneScanning for the highly sensitive detection of c-KIT somatic mutations in canine mast cell tumours. Vet Comp Oncol. 2015;13:218\u201328.","journal-title":"Vet Comp Oncol"},{"key":"2284_CR26","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1177\/104063870401600610","volume":"16","author":"R Preziosi","year":"2004","unstructured":"Preziosi R, Morini M, Sarli G. Expression of the KIT protein (CD117) in primary cutaneous mast cell tumors of the dog. J Vet Diagn Investig. 2004;16:554\u201361.","journal-title":"J Vet Diagn Investig"},{"key":"2284_CR27","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1354\/vp.44-3-298","volume":"44","author":"JD Webster","year":"2007","unstructured":"Webster JD, Yuzbasiyan-Gurkan V, Miller RA, Kaneene JB, Kiupel M. Cellular proliferation in canine cutaneous mast cell tumors: associations with c-KIT and its role in prognostication. Vet Pathol. 2007;44:298\u2013308.","journal-title":"Vet Pathol"},{"key":"2284_CR28","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1111\/j.1939-1676.2008.00132.x","volume":"22","author":"M Isotani","year":"2008","unstructured":"Isotani M, Ishida N, Tominaga M, Tamura K, Yagihara H, Ochi S, et al. Effect of tyrosine kinase inhibition by imatinib mesylate on mast cell tumors in dogs. J Vet Intern Med. 2008;22:985\u20138.","journal-title":"J Vet Intern Med"},{"key":"2284_CR29","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1111\/j.1365-2885.2011.01296.x","volume":"35","author":"Y Takeuchi","year":"2012","unstructured":"Takeuchi Y, Fujino Y, Fukushima K, Watanabe M, Nakagawa T, Ohno K, et al. Biological effect of tyrosine kinase inhibitors on three canine mast cell tumor cell lines with various KIT statuses. J Vet Pharmacol Ther. 2012;35:97\u2013104.","journal-title":"J Vet Pharmacol Ther"},{"key":"2284_CR30","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1111\/j.1939-1676.2004.tb02644.x","volume":"18","author":"R Zavodovskaya","year":"2004","unstructured":"Zavodovskaya R, Chien MB, London CA. Use of kit internal tandem duplications to establish mast cell tumor clonality in 2 dogs. J Vet Intern Med. 2004;18:915\u20137.","journal-title":"J Vet Intern Med"},{"key":"2284_CR31","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.vetimm.2011.04.002","volume":"142","author":"O Yamada","year":"2011","unstructured":"Yamada O, Kobayashi M, Sugisaki O, Ishii N, Ito K, Kuroki S, et al. Imatinib elicited a favorable response in a dog with a mast cell tumor carrying a c-KIT c1523A>T mutation via suppression of constitutive KIT activation. Vet Immunol Immunopathol. 2011;142:101\u20136.","journal-title":"Vet Immunol Immunopathol"},{"key":"2284_CR32","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1111\/j.1939-1676.2008.0190.x","volume":"22","author":"KA Hahn","year":"2008","unstructured":"Hahn KA, Ogilvie G, Rusk T, Devauchelle P, Leblanc A, Legendre A, et al. Masitinib is safe and effective for the treatment of canine mast cell tumors. J Vet Intern Med. 2008;22:1301\u20139.","journal-title":"J Vet Intern Med"},{"issue":"1","key":"2284_CR33","doi-asserted-by":"crossref","first-page":"4583","DOI":"10.1038\/s41467-018-06949-w","volume":"9","author":"CK Ip","year":"2018","unstructured":"Ip CK, Ng PK, Jeong KJ, Shao SH, Ju Z, Leonard PG, et al. Neomorphic PDGFRA extracellular domain driver mutations are resistant to PDGFRA targeted therapies. Nat Commun. 2018;9(1):4583.","journal-title":"Nat Commun"},{"key":"2284_CR34","doi-asserted-by":"crossref","first-page":"3856","DOI":"10.1158\/1078-0432.CCR-08-1860","volume":"15","author":"CA London","year":"2009","unstructured":"London CA, Malpas PB, Wood-Follis SL, Boucher JF, Rusk AW, Rosenberg MP, et al. Multi-center, placebo-controlled, double-blind, randomized study of oral toceranib phosphate (SU11654), a receptor tyrosine kinase inhibitor, for the treatment of dogs with recurrent (either local or distant) mast cell tumor following surgical excision. Clin Cancer Res. 2009;15:3856\u201365.","journal-title":"Clin Cancer Res"},{"key":"2284_CR35","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1182\/blood.V100.3.1014","volume":"100","author":"C Roche-Lestienne","year":"2002","unstructured":"Roche-Lestienne C, Soenen-Cornu V, Grardel-Duflos N, La\u00ef JL, Philippe N, Facon T, et al. Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571 and they can pre-exist to the onset of treatment. Blood. 2002;100:1014\u20138.","journal-title":"Blood"},{"key":"2284_CR36","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1007\/s00277-003-0644-y","volume":"82","author":"KA Kreuzer","year":"2003","unstructured":"Kreuzer KA, Le Coutre P, Landt O, Na IK, Schwarz M, Schultheis K, et al. Preexistence and evolution of imatinib mesylate-resistant clones in chronic myelogenous leukemia detected by a PNA-based PCR clamping technique. Ann Hematol. 2003;82:284\u20139.","journal-title":"Ann Hematol"},{"key":"2284_CR37","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.ccr.2009.11.022","volume":"17","author":"AB Turke","year":"2010","unstructured":"Turke AB, Zejnullahu K, Wu YL, Song Y, Dias-Santagata D, Lifshits E, et al. Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC. Cancer Cell. 2010;17:77\u201388.","journal-title":"Cancer Cell"},{"key":"2284_CR38","first-page":"5995","volume":"62","author":"C Ricci","year":"2002","unstructured":"Ricci C, Scappini B, Divoky V, Gatto S, Onida F, Verstovsek S, et al. Mutation in the ATP-binding pocket of the ABL kinase domain in an STI571-resistant BCR\/ABL-positive cell line. Cancer Res. 2002;62:5995\u20138.","journal-title":"Cancer Res"},{"key":"2284_CR39","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1038\/labinvest.3700628","volume":"87","author":"J Lasota","year":"2007","unstructured":"Lasota J, vel Dobosz AJ, Wasag B, Wozniak A, Kraszewska E, Michej W, et al. Presence of homozygous KIT exon 11 mutations is strongly associated with malignant clinical behavior in gastrointestinal stromal tumors. Lab Investig. 2007;87:1029\u201341.","journal-title":"Lab Investig"},{"key":"2284_CR40","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1038\/modpathol.2008.46","volume":"21","author":"LL Chen","year":"2008","unstructured":"Chen LL, Holden JA, Choi H, Zhu J, Wu EF, Jones KA, et al. Evolution from heterozygous to homozygous KIT mutation in gastrointestinal stromal tumor correlates with the mechanism of mitotic nondisjunction and significant tumor progression. Mod Pathol. 2008;21:826\u201336.","journal-title":"Mod Pathol"},{"key":"2284_CR41","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1038\/labinvest.2008.13","volume":"88","author":"JF Emile","year":"2008","unstructured":"Emile JF, Bachet JB, Tabone-Eglinger S, Terrier P, Vignault JM. GIST with homozygous KIT exon 11 mutations. Lab Investig. 2008;88:456\u20137.","journal-title":"Lab Investig"},{"issue":"1","key":"2284_CR42","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1097\/PAI.0b013e3181ec4f95","volume":"19","author":"ML Wallander","year":"2011","unstructured":"Wallander ML, Willmore-Payne C, Layfield LJ. C-KIT and PDGFRA zygosity in gastrointestinal stromal tumors: correlation with tumor site tumor size exon and CD117 immunohistochemistry. Appl Immunohistochem Mol Morphol. 2011;19(1):21\u20137.","journal-title":"Appl Immunohistochem Mol Morphol"},{"key":"2284_CR43","doi-asserted-by":"crossref","first-page":"e61103","DOI":"10.1371\/journal.pone.0061103","volume":"8","author":"JB Bachet","year":"2013","unstructured":"Bachet JB, Tabone-Eglinger S, Dessaux S, Besse A, Brahimi-Adouane S, Emile JF, et al. Gene expression patterns of hemizygous and heterozygous KIT mutations suggest distinct oncogenic pathways: a study in NIH3T3 cell lines and GIST samples. PLoS One. 2013;8:e61103.","journal-title":"PLoS One"},{"key":"2284_CR44","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.3892\/etm.2015.2613","volume":"10","author":"CW Xu","year":"2015","unstructured":"Xu CW, Lin S, Wang WL, Gao WB, Lv JY, Gao JS, et al. Analysis of mutation of the c-kit gene and PDGFRA in gastrointestinal stromal tumors. Exp Ther Med. 2015;10:1045\u201351.","journal-title":"Exp Ther Med"},{"key":"2284_CR45","doi-asserted-by":"crossref","first-page":"5352","DOI":"10.1200\/JCO.2007.15.7461","volume":"26","author":"MC Heinrich","year":"2008","unstructured":"Heinrich MC, Maki RG, Corless CL, Antonescu CR, Harlow A, Griffith D, et al. Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor. J Clin Oncol. 2008;26:5352\u20139.","journal-title":"J Clin Oncol"},{"key":"2284_CR46","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1016\/j.exphem.2010.05.004","volume":"38","author":"B Peter","year":"2010","unstructured":"Peter B, Hadzijusufovic E, Blatt K, Gleixner KV, Pickl WF, Thaiwong T, et al. KIT polymorphisms and mutations determine responses of neoplastic mast cells to bafetinib (INNO-406). Exp Hematol. 2010;38:782\u201391.","journal-title":"Exp Hematol"}],"container-title":["BMC Veterinary Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12917-020-02284-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12917-020-02284-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12917-020-02284-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,20]],"date-time":"2021-02-20T06:02:17Z","timestamp":1613800937000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcvetres.biomedcentral.com\/articles\/10.1186\/s12917-020-02284-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,19]]},"references-count":46,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["2284"],"URL":"https:\/\/doi.org\/10.1186\/s12917-020-02284-9","relation":{},"ISSN":["1746-6148"],"issn-type":[{"value":"1746-6148","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,19]]},"assertion":[{"value":"17 July 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 February 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 February 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study did not require official or institutional ethical approval as it was not experimental. The dog in this study was examined with the written consent of their owner who paid for the histological and molecular analysis. The aim was to identify the cause of the acquired disorder and thereby improve the animal welfare.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The owner signed an informed consent form including the authorization to publish the data arising from this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"MET and CD are affiliated with commercial laboratories carrying out veterinary testing. This does not alter our adherence to BMC vet res policies on sharing data and materials. There are no patent products in development or marketed products to declare.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"64"}}